Skip to main content

Specialty Pharmacy

  • Forbes: Pharma innovation getting harder as approvals fall

  • FDA approves Clovis Oncology’s Rubraca

    WASHINGTON, D.C. — The U.S. Food and Drug Administration approved Clovis Oncology’s Rubraca (rucaparib) for women with advanced ovarian cancer who have been treated with two or more chemotherapies and whose tumors have a specific gene mutation (deleterious BRCA) as identified by an FDA-approved companion diagnostic test.

  • Lilly, Boehringer Ingelheim launch Lantus follow-on Basaglar

    INDIANAPOLIS and RIDGEFIELD, Conn. — Eli Lilly and Co. and Boehringer Ingelheim Pharmaceuticals on Thursday announced the launch and availability of their Basaglar. The drug is a follow-on insulin to U-100 insulin glargine Lantus and is a long-acting insulin with an amino acid sequence identical to that of Lantus. 
     

  • Obama signs 21st Century Cures Act

    WASHINGTON — President Barack Obama on Tuesday signed the 21st Century Cures Act into law in a ceremony at the White House, where he introduced by Vice President Joe Biden. The act, one of the last the outgoing president is expected to sign, will invest more than $6 billion over seven years to provide funding for various initiatives, including fighting prescription drug abuse, expanding the president’s Precision Medication Initiative and funding the “cancer moonshot,” aimed at finding new and better treatments for cancer. 
     

  • Diplomat named National Standard amid Michigan’s Top Workplaces

    FLINT, Mich. — The Detroit Free Press has recognized Diplomat Pharmacy as one a 2016 Top Workplaces National Standard, the company announced Thursday. 
     
    The results come from an employee survey administered by research firm WorkplaceDynamics. The survey measured such aspects of workplace culture as alignment, execution and connection. This is the third year in a row the company has made the Top Workplaces list, and its fourth overall, having received the recognition in 2012 as well. 
     

  • Biotech stocks drop after Trump promises to ‘bring down drug prices’

    NEW YORK — Biotech stocks closed largely down on Tuesday, following a day of trading that began with a 2.5% drop in the SPDR S&P Biotech XBI index. The XBI closed down 4.02% and iShares Nasdaq Biotechnology ETF IBB closed down 2.94%. This is as the S&P closed up 1.32% and the Nasdaq closed up 1.14%. 
     

  • H-E-B Specialty Pharmacy receives full accreditations

    SAN ANTONIO — H-E-B on Tuesday annoubnced its H-E-B Specialty Pharmacy division has received full accreditation to deliver specialized clinical services to patients with complex and chronic diseases in more than 260 H-E-B stores across the state of Texas.

  • 21st Century Cures Act passes Senate, heads to Obama’s desk

    WASHINGTON — The Senate voted 94-5 on Wednesday to pass the 21st Century Cures Act, sending it to the desk of President Barack Obama. The act, which was passed by the House of Representatives on Nov. 30, includes funding to support the fight against prescription drug abuse and funding for the National Institutes of Health’s cancer initiative, known as Vice President Joe Biden’s “cancer moonshot” initiative, which was renamed by the Senate after Biden’s son, Beau, who died of cancer in 2015. 
     
X
This ad will auto-close in 10 seconds